Navigation Links
New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T
Date:11/7/2011

n increased risk for developing serious infections that may lead to hospitalization or death.  Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.  CIMZIA should be discontinued if a patient develops a serious infection or sepsis.  Reported infections include:

  • Active tuberculosis, including reactivation of latent tuberculosis.  Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease.  Patients should be tested for latent tuberculosis before CIMZIA use and during therapy.  Treatment for latent infection should be initiated prior to CIMZIA use.  
  • Invasive fungal infections, including histoplasmosis , coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis.  Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized disease.  Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection.  Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.
  • Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.

The risks and benefits of treatment with CIMZIA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.  Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with CIMZIA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

Lymphoma and other malignancies, some fatal, have been reported in childre
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... MOUNTAIN VIEW, Calif. , Aug. 31, 2015 ... market for flow cytometry is experiencing a rise ... is the demand in underdeveloped nations to quantitate ... patients. Logo - http://photos.prnewswire.com/prnh/20150831/262206LOGO ... Sullivan, Analysis of the Global Flow Cytometry Market ...
(Date:8/31/2015)... -- The departments of Drug and Alcohol Programs (DDAP) and ... to raise awareness for International Overdose Awareness Day to ... and help more Pennsylvanians with substance use ... Building Bridges to Recovery initiative. ... a disease that is fully treatable, if given the ...
(Date:8/31/2015)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ), the nation,s largest ... Chairman & CEO, and Sean Whelan , CFO, will ... Hagerman and Mr. Whelan are scheduled to participate in the ... on Wednesday, September 9, 2015 at 1:45 PM ET. ... to participate in the Robert W. Baird 2015 Healthcare Conference ...
Breaking Medicine Technology:Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 4Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Diplomat to Participate in Upcoming Investor Conferences 2
... Baby Girl with Hypophosphatasia Treated With ENB-0040 at Children,s ... , MONTREAL, Dec. 1 Enobia ... novel therapeutics for serious bone disorders, today announced that ... hypophosphatasia was dosed. Enobia is investigating Enzyme Replacement Therapy ...
... Genaera Corporation (Nasdaq: GENR ) today ... MSI-1436C-102 (Study 102), the multiple ascending dose Phase 1b ... 2 diabetics. MSI-1436 is a novel therapeutic for the ... centrally and peripherally to regulate insulin and leptin pathways ...
Cached Medicine Technology:Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3
(Date:8/31/2015)... ... August 31, 2015 , ... The Lisle family law ... William Scott has been nominated by his peers to earn a “Leading Lawyers” distinction. ... percent of attorneys in the state of Illinois. The nomination process is based on ...
(Date:8/31/2015)... ... August 31, 2015 , ... Patients who thought about ... who are interested in learning more about the procedure beyond the information found on ... Internationally recognized hair transplant surgeon Parsa Mohebi will be on hand to answer patients ...
(Date:8/31/2015)... ... September 01, 2015 , ... Neuropsychiatric Disease and Treatment ... on transcranial near-infrared laser phototherapy ”. , As corresponding author Dr Theodore Henderson ... untreatable - with mostly palliative treatments only - and now we have shown ...
(Date:8/31/2015)... ... August 31, 2015 , ... Dr. Paul Kovatis of Orthopedic Spine & Sports ... Dr. Kovatis treats all surgical and non-surgical disorders of the leg, ankle and foot. ... system, excluding the spine. , Dr. Paul Kovatis completed his orthopedic leg, ankle and ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... and digital marketing communications company announced today that it has officially launched a ... President, the new website and brand refresh are more closely aligned with the ...
Breaking Medicine News(10 mins):Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2Health News:Watch a Live Hair Transplant at Parsa Mohebi Hair Restoration’s Open House 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3
... For the fourth,consecutive year, the Surf City USA(R) Marathon ... for a fundraising event that is directly,responsible for changing the ... In the Fourth Annual "Run for Mobility", ... Marathon and 5K as a way to raise funds,that sends ...
... general is boosting rates of obesity, other woes, experts ... a strong link between media exposure and childhood obesity, ... reviewed 173 studies on media and health conducted over ... 80 percent of the studies concluded that higher amounts ...
... "frozen lozenge" provides breakthrough method to help medicine go down , ... "A spoonful of sugar helps the medicine go down" -- parents ... Insight Pharmaceuticals has introduced Sucrets(R) ICE -- unique, frozen single-use packages ... sore throats. , , ...
... Med (IM) welcomes new CEO, S.,Hart Williford. Williford joins ... extensive background as a leader in healthcare,software, revenue management, ... Founder and nine-year CEO, Dr. ... and development in all sectors, as he steps into,the ...
... can affect whole families, experts point out , , TUESDAY, Dec. ... toll not only on women,s wallets but on their health ... back on health care due to costs, according to a ... Resource Center, part of the U.S. Department of Health and ...
... Science, and Technology at the Sandra Day O,Connor College ... international conference on April 3-4, 2009, in Tempe, Ariz., ... to the highly anticipated report of the U.S. National ... Sciences Community." , In addition to experts from ...
Cached Medicine News:Health News:Surf City USA(R) Marathon Impacts the World 2Health News:TV, Internet Causing Kids Harm: Report 2Health News:New Sucrets(R) ICE Cools Sore Throat Pain 2Health News:Ingenious Med Hires New CEO to Maintain and Further Expand Company Development 2Health News:Economy Driving Women to Skimp on Health Care: Poll 2Health News:Economy Driving Women to Skimp on Health Care: Poll 3
The KM-500's unique viewing and alignment window lets you observe the targeted eye from any distance. Two rechargeable batteries provide continuous uninterrupted use. Each battery provides 60 minutes...
Non-dissolvable Herrick Lacrimal Plugs provide long-term lacrimal occlusion through partial blockage of the horizontal canaliculus....
... Provides quick freezing and quick ... gas system - cleans the ... Lightweight probe tips have high ... Retinal Detachment, Glaucoma and Intra-vitreal ...
... instant defrosting by reversible flow of gas ... cycle automatically. Lightweight probe tips have high ... I/A. The surgeon can select either of ... Surgeon can have a selection of Irrigation, ...
Medicine Products: